AOR™ Sponsors Diabetes Research

Dr. Michael Brownlee of the Albert Einstein College of Medicine in New York City has looked at the effect of benfotiamine in hyperglycemia and determined that "Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy". In an upcoming study, Dr. Brownlee and his team will use a daily dose of 225 mg of AOR’s benfotiamine to investigate its antioxidant effect and its influence on various diabetes parameters.

Benfotiamine is a fat-soluble form of vitamin B1 (thiamine) and has superior bioavailability that regular thiamin because of its greater ability at penetrating cellular membranes. Supplementation with Benfotiamine up regulates Thiamin Pyrophosphate, a coenzyme capable of inhibiting the conversion of Amadori products into Advanced Glycation end-products (AGE). AGE are the result of the permanent attachment of sugar molecules to amino acids. They lead to DNA damage and warped protein structures and are largely responsible for the rapid aging seen in diabetic patients. Benfotiamine is a powerful "late-phase" inhibitor of AGE formation and may prove to be capable of reducing the risk of diabetic complications.

For more information about Benfotiamine see: Benfotiamine.